Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

about

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

Item

http://www.wikidata.org/entity/Q58698690

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 23 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@en

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@nl

type

Item

label

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@en

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@nl

prefLabel

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@en

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@nl

P1476

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

@en

P2093

Holly L Pacenta

http://www.w3.org/2001/XMLSchema#string

Margaret E Macy

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Identification of ALK as a major familial neuroblastoma predisposition gene

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Emerging importance of ALK in neuroblastoma

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

P304

3549-3561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S147384

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425456

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

P932

6204873

http://www.w3.org/2001/XMLSchema#string